Review Article

ApoA-I/HDL Generation and Intracellular Cholesterol Transport through Cytosolic Lipid-Protein Particles in Astrocytes

Jinichi Ito and Makoto Michikawa

Biochemistry, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan

Correspondence should be addressed to Jinichi Ito; jitoh@med.nagoya-cu.ac.jp

Received 20 May 2014; Accepted 24 June 2014; Published 13 August 2014

Copyright © 2014 J. Ito and M. Michikawa. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Exogenous apolipoprotein A-I (apoA-I) associates with ATP-binding cassette transporter A1 (ABCA1) on the cell surface of astrocytes like various peripheral cells and enhances the translocation of newly synthesized cholesterol from the endoplasmic reticulum/Golgi apparatus (ER/Golgi) to the cytosol. The cholesterol translocated to the cytosol is incorporated to cytosolic lipid-protein particles (CLPP) together with phospholipids and proteins such as sphingomyelin, phosphatidylcholine, caveolin-1, protein kinase C_\(\alpha\) (PK-C_\(\alpha\)), and cyclophilin A. The CLPP are high density lipoproteins- (HDL-) like cytosolic lipid-protein complex with densities of 1.09–1.16 g/mL and diameters of 17-18 nm. The association of exogenous apoA-I with cellular ABCA1 induces tyrosine phosphorylation, activation, and translocation to the CLPP of ABCA1-associated phospholipase C_\(\gamma\) (PL-C_\(\gamma\)) in astrocytes. Furthermore, PK-C_\(\alpha\) is translocated and activated to/in the CLPP through the production of diacylglyceride in the CLPP. ApoA-I enhances both the association of CLPP with microtubules and the phosphorylation of \(\alpha\)-tubulin as a component of microtubules. The CLPP are dissociated from microtubules after \(\alpha\)-tubulin in microtubules is phosphorylated by the CLPP-associated PK-C_\(\alpha\). The association and dissociation between CLPP and microtubules may participate in the intracellular transport of cholesterol to the plasma membrane.

1. Introduction

Many lines of evidence of the relationship between cholesterol metabolism and diseases such as atherosclerosis [1–3], Tangier disease [4, 5], Niemann–Pick disease type C [6, 7], and Alzheimer’s disease [8, 9] led to an erroneous notion that cholesterol is harmful to human health. Therefore, these lines of evidence indicate that cholesterol homeostasis is significant for the maintenance of human health. Cholesterol is an important lipid component of the cell membrane and regulates the fluidity and viscosity of the cell membrane by localizing among hydrocarbon chains of phospholipid molecules in the lipid bilayer [10, 11]. Cholesterol molecule, furthermore, constructs membrane lipid rafts along with sphingomyelin, which are cholesterol- and sphingomyelin-rich microdomains and are platforms for various proteins participating in signal transductions through the plasma membrane [12, 13].

Various types of cells generally synthesize cholesterol to keep membrane cholesterol level for the maintenance of cell function and survival. The cells also obtain cholesterol from low density lipoproteins (LDL) in the blood through the interaction with the LDL receptor on the cell surface [14]. The incorporated cholesterol molecule is hardly digested in almost all the cell types besides the cell types such as hepatocytes and steroid hormone-producing cells, because of a stubborn cyclopentanoperhydrophenanthrene structure of the cholesterol molecule. Therefore, excess cellular cholesterol and oxidative cholesterol must be allowed to extrude to the extracellular space and be transported to the liver [15]. Investigating the mechanisms underlying intracellular cholesterol transport and release of cholesterol to the extracellular space as high density lipoproteins (HDL) is very important for clarifying cholesterol homeostasis for the maintenance of cellular cholesterol level and prevention of cholesterol hyperaccumulation. However, the analysis of
in intracellular localization and movement of the cholesterol molecule after cholesterol biosynthesis is technically very difficult. The detailed mechanisms underlying the intracellular transport and efflux of de novo synthesized cholesterol through the interaction with exogenous apolipoproteins remain unclarified despite many previous investigations.

The central nervous system (CNS) is rich in cholesterol, which accounts for 20–25% of the total body cholesterol in humans, and neurons in the CNS are highly dependent on cholesterol for their survival and function. In cultured cell systems, suppression of cholesterol synthesis decreases the viability of neurons and addition of cholesterol as apoE/HDL results in resumption of synapse formation and neurite outgrowth [16–19], suggesting that apoE functions as an intercellular cholesterol transporter in the brain. However, the CNS in vertebrates is segregated by the blood-brain barrier (BBB) from the systemic circulation; therefore, apoE in plasma seems to be produced within the CNS [20]. Interestingly, recent studies have shown that apoE regulates BBB formation to control the integrity of tight junctions of BBB in an apoE-isofrom-dependent manner in vitro and in vivo [21, 22]. Because BBB is a site for brain Aβ clearance to the blood, apoE-isofrom-specific regulation of BBB function(s) may explain the mechanism underlying apoE4-accelerated development of Alzheimer disease.

Astrocytes in the CNS not only produce and secrete apolipoprotein E (apoE) as HDL containing apoE (apoE/HDL) [23, 24] but also generate apoA-I/HDL through the interaction of cell surface with exogenous apoA-I [25, 26]. As the most abundant apolipoproteins in human cerebral fluid (CSF) are apoE and apoA-I [27–29], astrocytes are considered to play an important role in intercellular cholesterol transport in the CNS. We have been studying the mechanism underlying cholesterol efflux and intercellular cholesterol transport in astrocytes to clarify cholesterol homeostasis in the CNS. We found that HDL-like particles (cytosolic lipid-protein particles, CLPP) composed of lipid-protein complex in the cytosol participate in intracellular cholesterol transport through the interaction between CLPP and microtubules in astrocytes treated with exogenous apoA-I [30–32]. In this review, the mechanism underlying intracellular cholesterol transport in astrocytes treated with exogenous apolipoproteins, particularly apoA-I, is described on the basis of experimental data obtained in our laboratory.

2. Production and Function of ApoE and ApoA-I in the Brain

There are many studies of the mechanism underlying apoE secretion using macrophages [33–38]. After the biosynthesis in the ER, some of the apoE molecules are secreted from the plasma membrane through O-linked glycosylation in the Golgi [37], while other large parts of apoE are digested in the lysosomes. In macrophages, the secreted apoE is reinternalized by macrophages for the generation of apoE/HDL [34, 38]. ApoE appears to be secreted from macrophages to depend on the functions of protein kinase A and microtubules via a calcium-dependent pathway [36]. The mechanisms underlying apoE secretion and apoE/HDL generation in the brain are unclear at present. We have been studying the mechanism underlying apoE secretion using astrocytes prepared from the fetal rat brain. We found that the apoE secretion starts within 30 min after the initiation of apoE synthesis in rat astrocytes. An endogenous apoE is localized in the lipid rafts/caveolaed domains in the manner dependent on the interaction with ABCA1 in wild type of astrocytes. The apoE is distributed in the nonraft fraction in the membrane fraction from ABCA1-KO astrocytes. Wild-type mouse astrocytes secrete apoE as apoE/HDL with densities of 1.08–1.12 g/mL, whereas the astrocytes prepared from ABCA1-KO mice secrete apoE as insufficiently lipitated HDL with higher density (d = 1.12–1.17 g/mL), suggesting that the lipidation of apoE depends on the function of ABCA1 in the membrane lipid rafts of astrocytes [39].

HDL-associated apolipoproteins found in cerebrospinal fluid (CSF) are predominantly apoE and apoA-I, in addition to minor apolipoproteins such as apolipoproteins A-IV, D, and J [40, 41]. As apoA-I with a molecular weight of 27 kDa is the second most abundant apolipoprotein next to apoE in the cerebrospinal fluid (CSF), apoA-I is also considered to contribute to cholesterol homeostasis in the brain along with apoE. The source of apoA-I is not clear, while apoE and apoJ are produced and secreted by astrocytes. Although apoA-I mRNA is hardly found in the brain, there are a few reports that apoA-I is produced by the capillary endothelial cells in the brain [42, 43]. ApoA-I in the CNS may be derived also from plasma through the blood-brain barrier (BBB). Astrocytes do not apparently secrete apoA-I. It is possible for astrocytes to interact with exogenous apoA-I secreted by endothelial cells in the brain. We showed that rat astrocytes generate biochemically different HDL through exogenous apoA-I and endogenous apoE-mediated cholesterol release, suggesting different roles between apoA-I/HDL and apoE/HDL in the brain. ApoA-I especially seemingly participates in removal of excess cholesterol from the brain to outside of the BBB to convert 24(S)OH-cholesterol as a more polar molecule [44]. As 24(S)OH-cholesterol is a high affinity ligand for LXRα and LXRβ, this sterol enhances expression of ABCA1 to upregulate cholesterol efflux. Scavenger receptor class B type 1 (SR-B1) in endothelial cells effectively supports the reverse of apoA-I-mediated sterol transport. Such a system to transport cholesterol to outside of the brain through the BBB may be favorable for removal of excess cholesterol in the brain, as brain capillary endothelial cells form the BBB along with astrocytes.

The levels of cholesterol and apoA-I in plasma HDL have been known to be low in patients with Alzheimer’s disease, suggesting that high levels of apoA-I/HDL reduce the risk of cardiovascular disease. Lewis et al. showed that overexpression of human apoA-I is effective to preserve cognitive function in a mouse model of Alzheimer’s disease through reducing Aβ-induced production of chemokines/cytokines [45]. However, there are some reports that high levels of apoA-I/HDL in plasma are not effective to protect Alzheimer’s disease [46]. Haploinsufficiency of angiogenin, furthermore, is a risk factor of Alzheimer’s disease. Amyloidogenic variant of apoA-I apparently induces cell death through reducing...
It has been shown that lipid-free apoA-I generates preß-HDL-induced cholesterol efflux through the interaction between ABCG1 [64–66]. Karten et al. has shown that HDL matures to cholesterol-rich HDL with a lower density through the interaction with ABCA1 and that preß-HDL generates cholesterol-rich HDL with a lower density through their interaction with ABCG1 [64–66].

3. Generation of ApoA-I-Containing HDL in Astrocytes

Astrocytes synthesize and secrete apoE as cholesterol-rich apoE/HDL [24], which are taken up by neurons through apoE receptors. Although neurons produce cholesterol, additional amounts of cholesterol from astrocytes as apoE/HDL are required for the formation of numerous synapses in the CNS [18]. It has been reported that the production of apoE/HDL in the CNS also depends on ABCA1 [48–51]. However, it is unclear how ABCA1 regulates the secretion and lipidation of apoE in CNS cells.

On the other hand, astrocytes generate HDL through the interaction between exogenous lipid-free apoA-I and ABCA1 on their cell surfaces similarly to peripheral cells [52]. ApoA-I/HDL generated in astrocytes through the interaction with exogenous apoA-I is more cholesterol-poor and phospholipid-rich than apoE/HDL generated by endogenous apoE in astrocytes [25, 30]. The differences in features between apoA-I/HDL and apoE/HDL are considered to depend on differences in features between apoA-I and apoE. The mechanism underlying apoA-I/HDL generation may be different from that underlying apoE/HDL generation. Because apoA-I is an activator of lecithin-cholesterol acyl-transferase (LCAT), which is expressed in the brain [53], apoA-I must participate in intercellular cholesterol transport in the CNS as in the case of peripheral cholesterol transport.

ApoA-I in the plasma enhances efflux of cholesterol and phospholipids from the cell surface of many kinds of peripheral cells to generate HDL through the interaction with ABCA1. ABCA1 is a membrane-penetrating protein with a molecular weight of 250 kDa [54–56], and its deficiency is known to cause Tangier disease without HDL in the plasma. Although neurons produce cholesterol, additional amounts of cholesterol from astrocytes as apoE/HDL are required for the formation of numerous synapses in the CNS [18]. It has been reported that the production of apoE/HDL in the CNS also depends on ABCA1 [48–51]. However, it is unclear how ABCA1 regulates the secretion and lipidation of apoE in CNS cells.

On the other hand, astrocytes generate HDL through the interaction between exogenous lipid-free apoA-I and ABCA1 on their cell surfaces similarly to peripheral cells [52]. ApoA-I/HDL generated in astrocytes through the interaction with exogenous apoA-I is more cholesterol-poor and phospholipid-rich than apoE/HDL generated by endogenous apoE in astrocytes [25, 30]. The differences in features between apoA-I/HDL and apoE/HDL are considered to depend on differences in features between apoA-I and apoE. The mechanism underlying apoA-I/HDL generation may be different from that underlying apoE/HDL generation. Because apoA-I is an activator of lecithin-cholesterol acyl-transferase (LCAT), which is expressed in the brain [53], apoA-I must participate in intercellular cholesterol transport in the CNS as in the case of peripheral cholesterol transport.

ApoA-I in the plasma enhances efflux of cholesterol and phospholipids from the cell surface of many kinds of peripheral cells to generate HDL through the interaction with ABCA1. ABCA1 is a membrane-penetrating protein with a molecular weight of 250 kDa [54–56], and its deficiency is known to cause Tangier disease without HDL in the plasma. Although neurons produce cholesterol, additional amounts of cholesterol from astrocytes as apoE/HDL are required for the formation of numerous synapses in the CNS [18]. It has been reported that the production of apoE/HDL in the CNS also depends on ABCA1 [48–51]. However, it is unclear how ABCA1 regulates the secretion and lipidation of apoE in CNS cells.

On the other hand, astrocytes generate HDL through the interaction between exogenous lipid-free apoA-I and ABCA1 on their cell surfaces similarly to peripheral cells [52]. ApoA-I/HDL generated in astrocytes through the interaction with exogenous apoA-I is more cholesterol-poor and phospholipid-rich than apoE/HDL generated by endogenous apoE in astrocytes [25, 30]. The differences in features between apoA-I/HDL and apoE/HDL are considered to depend on differences in features between apoA-I and apoE. The mechanism underlying apoA-I/HDL generation may be different from that underlying apoE/HDL generation. Because apoA-I is an activator of lecithin-cholesterol acyl-transferase (LCAT), which is expressed in the brain [53], apoA-I must participate in intercellular cholesterol transport in the CNS as in the case of peripheral cholesterol transport.

4. Exogenous ApoA-I-Mediated Intracellular Cholesterol Transport

We observed that the newly synthesized cholesterol and phospholipids such as phosphatidylcholine and sphingomyelin are transiently translocated from the ER/Golgi to the cytosol in rat astrocytes treated with exogenous human apoA-I for 90 min [31]. The cholesterol and phospholipids translocated to the cytosol were recovered with the cytosolic fraction with densities of 1.09–1.16 g/mL like plasma HDL [31]. Proteins such as caveolin-1 and cyclophilin A are also translocated to this fraction in the cytosol of rat astrocytes after the apoA-I treatment for 90 min. A cyclophilin A-specific inhibitor, cyclosporin A, suppressed not only the translocation of newly synthesized lipid and caveolin-1 to the cytosol but also the cholesterol efflux in apoA-I-treated rat astrocytes [31, 68]. These findings suggest that the newly synthesized cholesterol and phospholipids exist as lipoprotein-like particles together with proteins such as caveolin-1 and cyclophilin A in the cytosol. The electron microscopic observation showed HDL-like lipid-protein particles with diameters of 17–18 nm and we referred to them as cytosolic lipid-protein particles (CLPP) [31]. Because CLPP are soluble in Triton X-100, it is considered that CLPP are not derived from the lipid rafts/caveolae domain, although caveolin-1 is transported to the CLPP from the lipid rafts/caveolae domain.

As the syntheses of cholesterol and phospholipids are enhanced in rat astrocytes at 2 h after apoA-I treatment, it is suggested that the apoA-I-induced lipid translocation from ER/Golgi to cytosol precedes the increase of lipid synthesis. The processing of SREBP1 and SREBP2 more than 60 min after the treatment with apoA-I is actually enhanced and the mature forms of these proteins were transported to the nuclei [31]. The maturation of SREBPs may proceed to stimulate the transcription of enzymes relating to the syntheses of lipids such as cholesterol and phospholipids, because the cholesterol level in the ER membrane must be decreased by cholesterol translocation to the CLPP in the cytosol after the apoA-I treatment. These findings suggest that the collaboration between cyclophilin A and caveolin-1 is required in the intracellular transport of newly synthesized cholesterol from the ER/Golgi to the plasma membrane and apoA-I-mediated cholesterol efflux. The CLPP appear to function as vehicles for the intracellular transport of cholesterol (Figure 1).

We examined whether exogenous apoA-I associates with ABCA1 in rat astrocytes like peripheral cells. We found by western blotting analysis that apoA-I comigrated with ABCA1 with an apparent molecular weight of over 260 kDa in rat astrocytes treated with apoA-I and then with a crosslinker, BS3 [52]. ApoA-I-bound ABCA1 was isolated by anti-apoA-I antibody-bound Protein G-Sepharose.
The solubilized ABCA1 in the membrane fraction of rat astrocytes, furthermore, bound to apoA-I-immobilized AffiGel 15. LXR agonist, To901317, enhances both cellular level of ABCA1 and binding of apoA-I to ABCA1. Phospholipase C\(\gamma\) (PL-C\(\gamma\)) is coisolated with ABCA1 from the solubilized membrane fraction of rat astrocytes using apoA-I-immobilized AffiGel 15 or using anti-ABCA1 antibody-bound Protein G/Sepharose [52]. These findings suggest that exogenous apoA-I binds to the extracellular domain of ABCA1 that associates with PL-C\(\gamma\) at the intracellular site in astrocytes.

ApoA-I induces the tyrosine phosphorylation of PL-C\(\gamma\) in rat astrocytes at 5 min after apoA-I stimulation, followed by the translocation of PL-C\(\gamma\) to the CLPP fraction and diacylglyceride production in the CLPP. The SiRNA of ABCA1 suppressed not only the PL-C\(\gamma\) binding to ABCA1 but also the apoA-I-induced tyrosine phosphorylation of PL-C\(\gamma\). The protein kinase C\(\alpha\) (PK-C\(\alpha\)) translocation to and its activation in the CLPP are also continuously enhanced in apoA-I-treated rat astrocytes [30]. The suppression of either phospholipase C or protein kinase C inhibits apoA-I-mediated cholesterol release and apoA-I/HDL generation. These findings suggest that the CLPP are intracellular sites of apoA-I-induced signal transduction and function as intracellular cholesterol transport vehicles.

5. Function of Sphingomyelin in Intracellular Cholesterol Transport

Many reports show that cholesterol is specifically associated with sphingomyelin rather than other phospholipids in the plasma membrane [69–71]. The membrane lipid rafts are cholesterol- and sphingomyelin-rich membrane microdomains and indicate an important feature that may contribute to signalings through the plasma membrane. Caveolin-1, furthermore, forms an invagination in cholesterol- and sphingomyelin-rich membrane microdomains as caveolae. It is expected that when cells are treated with sphingomyelinase (SMase), sphingomyelin is digested in the cell surface, which is followed by cholesterol redistribution and destruction of lipid raft/caveolae in the plasma membrane. Therefore,
the treatment of astrocytes with SMase may influence apoA-I-mediated cholesterol release and intracellular cholesterol transport through the decrease in sphingomyelin level and the unstability of cholesterol localization in the plasma membrane. ApoA-I-mediated cholesterol efflux from the cell surface is actually enhanced in SMase-treated rat astrocytes. The addition of exogenous sphingomyelin suppressed conversely the apoA-I-mediated cholesterol release. De novo synthesis of sphingomyelin is enhanced after the SMase treatment and then apoA-I-mediated cholesterol efflux is gradually suppressed [72].

Sphingomyelin may function as an anchor of cholesterol in the plasma membrane, particularly in the lipid rafts/caveolae domain. This is also supported by the report by Nagao et al. that exogenously added sphingomyelin significantly inhibits the apoA-I-dependent cholesterol efflux from sphingomyelin-deficient Chinese hamster ovary cells [73].

Surprisingly, the suppression of sphingomyelin synthesis using D609 (a phosphatidylcholine-specific phospholipase C inhibitor) after the SMase treatment markedly inhibits apoA-I-mediated cholesterol release, which is contrary to our expectation. We examined how sphingomyelin participates in intracellular cholesterol transport in rat astrocytes. Our experimental results suggest that sphingomyelin is synthesized through the transfer of a phosphorylcholine group to ceramide from phosphatidylcholine in apoA-I-stimulated rat astrocytes like SMase-treated cells [32]. D609 suppressed not only apoA-I-mediated cholesterol efflux but also cholesterol translocation from the ER/Golgi to the cytosol without inhibiting HMG-CoA reductase activity [32]. This finding suggests that sphingomyelin functions as one of the factors that stimulate the translocation of newly synthesized cholesterol to the cytosol from the ER/Golgi for intracellular cholesterol transport to the plasma membrane in addition to an anchor of cholesterol to regulate apoA-I-mediated cholesterol efflux. It is considered that diacylglyceride, which is produced during sphingomyelin synthesis, participates in intracellular cholesterol transport through the activation of PK-C. We demonstrated on the base of other experiments that ApoA-induced PK-Cα activation has a great role in the intracellular cholesterol transport in astrocytes.

6. Interaction between CLPP and Microtubules to Regulate Intracellular Cholesterol Transport and ApoA-I-Mediated Cholesterol Efflux

We found that the interaction between CLPP and microtubules is important to promote intracellular cholesterol transport for apoA-mediated cholesterol efflux from rat astrocytes. The association of CLPP with microtubule-like filaments (rMT) reconstituted in vitro using the cytosol fraction prepared from rat astrocytes stimulated with apoA-I was examined in order to show the association of CLPP and microtubules. The cytosol fraction was incubated with bovine tubulin-immobilized AffiGel 10 (bovine tubulin/AffiGel) under the microtubule-polymerization condition to construct bovine tubulin/AffiGel-associated rMT. The binding of CLPP-related cytosolic caveolin-1 and PK-Cα to bovine tubulin/AffiGel-associated rMT was more actively increased in the cytosol of rat astrocytes treated with apoA-I for 5 min than in the control cytosol without apoA-I treatment [74]. This finding suggests that apoA-I enhances the association of CLPP and microtubules in rat astrocytes (Figure 2). This association between rMT and CLPP is inhibited by addition of a scaffolding domain peptide of caveolin-1, suggesting that apoA-I enhances the association of microtubules and CLPP through the CLPP-binding caveolin-1. Furthermore, dysfunction of microtubules induced by Taxol suppresses not only the translocation of newly synthesized lipids such as cholesterol and phosphatidylcholine to the cytosol but also lipid release mediated by apoA-I. It is considered on the base of these findings that the intracellular cholesterol transport is promoted by microtubules in rat astrocytes treated with apoA-I. We thus suggested that intracellular cholesterol transport is mediated by cytosolic particles, CLPP, and apoA-I. The cytosolic sphingomyelin is synthesized through the transfer of a phosphorylcholine group to ceramide from phosphatidylcholine in apoA-I-stimulated rat astrocytes like SMase-treated cells [32]. D609 suppressed not only apoA-I-mediated cholesterol efflux but also cholesterol translocation from the ER/Golgi to the cytosol without inhibiting HMG-CoA reductase activity [32]. This finding suggests that sphingomyelin functions as one of the factors that stimulate the translocation of newly synthesized cholesterol to the cytosol from the ER/Golgi for intracellular cholesterol transport to the plasma membrane in addition to an anchor of cholesterol to regulate apoA-I-mediated cholesterol efflux. It is considered that diacylglyceride, which is produced during sphingomyelin synthesis, participates in intracellular cholesterol transport through the activation of PK-C. We demonstrated on the base of other experiments that ApoA-induced PK-Cα activation has a great role in the intracellular cholesterol transport in astrocytes.

7. Conclusions

Cholesterol is a very important membrane lipid to keep function and survival of neurons in the brain. Astrocytes supply neurons with cholesterol through HDL generation and intracellular cholesterol transport in rat astrocytes stimulated with exogenous apoA-I in this paper.
Figure 2: Reconstitution of microtubule-like filaments (rMT) using cytosol fraction prepared from rat astrocytes (a) and scheme of association of cytosolic lipid-protein particles (CLPP) and rMT through AffiGel-immobilized bovine tubulins.

Figure 3: Hypothesis of intracellular transport of CLPP through phosphorylation of α-tubulin in microtubules after interaction between apoA-I and ABCA1.
We showed a hypothesis of the mechanism for intracellular transport of newly synthesized cholesterol to the plasma membrane from the ER/Golgi through cytosolic lipid-protein particles (CLPP) after the interaction between exogenous apoA-I and ABCA1 on the cell surface of rat astrocytes. CLPP are mainly composed of lipids such as cholesterol, phosphatidylcholine, and sphingomyelin and proteins such as caveolin-1, cyclinophil A, and protein kinase Cα. After the interaction between apoA-I and ABCA1 in astrocytes, cholesterol and phospholipids biosynthesized in the ER/Golgi and caveolin-1 are translocated to the CLPP. Furthermore, the ABCA1-associated phospholipase Cγ is activated and translocated to the CLPP. The CLPP are associated with nonphosphorylated α-tubulin in the microtubules and then the CLPP go away from the phosphorylated α-tubulin in the microtubules. Thus, the CLPP are considered to be associated with next nonphosphorylated α-tubulin in microtubules to move to plasma membrane for the supply of newly synthesized lipids to the plasma membrane. Although our hypothesis shows intracellular cholesterol transport through particles of lipids-proteins complex but not vesicles, this does not deny other mechanisms for intracellular cholesterol transport through cellular vesicles.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] G. Assmann, A. M. Gotto, and M. DPhil, “HDL cholesterol and protective factors in atherosclerosis,” Circulation, vol. 109, supplement 3, pp. 8–14, 2004.
[2] P. Barter, “The role of HDL-cholesterol in preventing atherosclerotic disease,” European Heart Journal, Supplement, vol. 7, pp. F4–F8, 2005.
[3] U. Ravnskov, “Is atherosclerosis caused by high cholesterol?” Oxford Journal Medicine, vol. 95, no. 6, pp. 397–403, 2002.
[4] M. E. Brousseau, G. P. Eberhart, J. Dupuis et al., “Cellular cholesterol efflux in heterozygotes for Tangier disease is markedly reduced and correlates with high density lipoprotein cholesterol concentration and particle size,” Journal of Lipid Research, vol. 41, no. 7, pp. 1125–1135, 2000.
[5] A. T. Remaley, U. K. Schumacher, J. A. Stonik et al., “Decreased reverse cholesterol transport from Tangier Disease fibroblasts,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, pp. 1813–1821, 1997.
[6] T. Chang, P. C. Reid, S. Sugii, N. Ohgami, J. C. Cruz, and C. C. Y. Chang, “Niemann-Pick type C disease and intracellular cholesterol trafficking,” Journal of Biological Chemistry, vol. 280, no. 22, pp. 20917–20920, 2005.
[7] M. Kosicek, M. Malnar, A. Goate, and S. Hecimovic, “Cholesterol accumulation in Niemann-Pick type C (NPC) model cells causes a shift in APP localization to lipid rafts,” Biochemical and Biophysical Research Communications, vol. 393, no. 3, pp. 404–409, 2010.
[8] N. Arispe and M. Doh, “Plasma membrane cholesterol controls the cytotoxicity of Alzheimer’s disease AβP (1–40) and (1–42) peptides,” The FASEB Journal, vol. 16, no. 12, pp. 1526–1536, 2002.
[9] M. Michikawa, “Cholesterol paradox: Is high total or low HDL cholesterol level a risk for Alzheimer’s disease?” Journal of Neuroscience Research, vol. 72, no. 2, pp. 141–146, 2003.
[10] R. A. Cooper, “Influence of increased membrane cholesterol on membrane fluidity and cell function in human red blood cells,” Journal of Supramolecular and Cellular Biochemistry, vol. 8, no. 4, pp. 413–430, 1978.
[11] S. Raffy and J. Teissié, “Control of lipid membrane stability by cholesterol content,” Biophysical Journal, vol. 76, no. 4, pp. 2072–2080, 1999.
[12] K. B. Kannan, D. Barlos, and C. J. Hauser, “Free cholesterol alters lipid raft structure and function regulating neutrophil Ca2+ entry and respiratory burst: Correlations with calcium channel raft trafficking,” Journal of Immunology, vol. 178, no. 8, pp. 5253–5261, 2007.
[13] Z. Korade and A. K. Kenworthy, “Lipid rafts, cholesterol, and the brain,” Neuropharmacology, vol. 55, no. 8, pp. 1265–1273, 2008.
[14] J. L. Goldstein and M. S. Brown, “The LDL receptor,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 4, pp. 431–438, 2009.
[15] R. Ohashi, H. Mu, X. Wang et al., “Reverse cholesterol transport and cholesterol efflux in atherosclerosis,” Oxford Journals Medicine, vol. 98, pp. 845–856, 2005.
[16] R. B. DeMattos, L. K. Curtiss, and D. L. Williams, “A minimally lipidated form of cell-derived apolipoprotein E exhibits isoform-specific stimulation of neurite outgrowth in the absence of exogenous lipids or lipoproteins,” The Journal of Biological Chemistry, vol. 273, no. 7, pp. 4206–4212, 1998.
[17] A. M. Fagan, G. Bu, Y. Sun, A. Daugherty, and D. M. Holtzman, “Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein,” Journal of Biological Chemistry, vol. 271, no. 47, pp. 30121–30125, 1996.
[18] H. Hayashi, R. B. Campenot, D. E. Vance, and J. E. Vance, “Apolipoprotein E-containing lipoproteins protect neurons from apoptosis via a signaling pathway involving low-density lipoprotein receptor-related protein-1,” Journal of Neuroscience, vol. 27, no. 8, pp. 1933–1941, 2007.
[19] D. H. Mauch, K. Nágier, S. Schumacher et al., “CNS synaptogenisis promoted by glia-derived cholesterol,” Science, vol. 294, no. 5545, pp. 1354–1357, 2001.
[20] M. F. Linton, R. Gish, S. T. Hubl et al., “Phenotypes of apoA-Ideficient mice,” Journal of Clinical Investigation, vol. 88, no. 1, pp. 270–281, 1991.
[21] R. D. Bell, E. A. Winkler, I. Singh et al., “Apolipoprotein e containing lipoproteins protect neurons from apoptosis via a signaling pathway involving low-density lipoprotein receptor-related protein-1,” Journal of Biological Chemistry, vol. 270, no. 5, pp. 2526–2536, 2005.
[22] K. Nishitsuji, T. Hosono, T. Nakamura, G. Bu, and M. Michikawa, “Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-brain barrier model,” Journal of Biological Chemistry, vol. 286, no. 20, pp. 17536–17542, 2011.
nervous system,” The Journal of Clinical Investigation, vol. 76, no. 4, pp. 1501–1513, 1985.

[24] S. C. Fujita, K. Sakuta, R. Tsuchiya, and H. Hamanaka, “Apolipoprotein E is found in astrocytes but not in microglia in the normal mouse brain,” Neuroscience Research, vol. 35, no. 2, pp. 123–133, 1999.

[25] J. Ito, L. Y. Zhang, M. Asai, and S. Yokoyama, “Differential generation of high-density lipoprotein by endogenous and exogenous apolipoproteins in cultured fetal rat astrocytes,” Journal of Neurochemistry, vol. 72, no. 6, pp. 2362–2369, 1999.

[26] L. Zhang, J. Ito, T. Kato, and S. Yokoyama, “Cholesterol homeostasis in rat astrocytoma cells Ga-1,” Journal of Biochemistry, vol. 128, no. 5, pp. 837–845, 2000.

[27] I. Borghini, F. Barja, D. Pometta, and R. W. James, “Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid,” Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism, vol. 1255, no. 2, pp. 192–200, 1995.

[28] H. Chiba, T. Mitamura, S.-. Fujiwara et al., “Apolipoproteins in rat cerebrospinal fluid: a comparison with plasma lipoprotein metabolism and effect of aging,” Neuroscience Letters, vol. 133, no. 2, pp. 207–210, 1991.

[29] S. Koch, N. Donarski, K. Goetze et al., “Characterization of four lipoprotein classes in human cerebrospinal fluid,” Journal of Lipid Research, vol. 42, no. 7, pp. 1143–1151, 2001.

[30] J. Ito, H. Li, Y. Nagayasu, A. Kheirollah, and S. Yokoyama, “Apolipoprotein A-I induces translocation of protein kinase Ca to a cytosolic lipid-protein particle in astrocytes,” Journal of Lipid Research, vol. 45, no. 12, pp. 2269–2276, 2004.

[31] J. Ito, Y. Nagayasu, K. Kato, R. Sato, and S. Yokoyama, “Apolipoprotein A-I induces translocation of cholesterol, phospholipid, and caveolin-1 to cytosol in rat astrocytes,” Journal of Biological Chemistry, vol. 277, no. 10, pp. 7929–7935, 2002.

[32] J. Ito, Y. Nagayasu, S. Ueno, and S. Yokoyama, “Apolipoprotein-mediated cellular lipid release requires replenishment of sphingomyelin in a phosphatidylcholine-specific phospholipase C-dependent manner,” Journal of Biological Chemistry, vol. 277, no. 47, pp. 44709–44714, 2002.

[33] N. A. Braun, P. J. Mohler, K. H. Weisgraber et al., “Intracellular trafficking of recycling apolipoprotein E in Chinese hamster ovary cells,” Journal of Lipid Research, vol. 47, no. 6, pp. 1176–1186, 2006.

[34] J. Deng, V. Rudick, and L. Dory, “Lysosomal degradation and sorting of apolipoprotein E in macrophages,” Journal of Lipid Research, vol. 36, no. 10, pp. 2129–2140, 1995.

[35] J. Heeren, T. Grewal, A. Laatsch et al., “Impaired recycling of apolipoprotein E4 is associated with intracellular cholesterol accumulation,” Journal of Biological Chemistry, vol. 279, no. 53, pp. 55483–55492, 2004.

[36] M. Kockx, D. L. Guo, T. Huby et al., “Secretion of apolipoprotein E from macrophages occurs via a protein kinase A- and calcium-dependent pathway along the microtubule network,” Circulation Research, vol. 101, no. 6, pp. 607–616, 2007.

[37] V. I. Zannis, J. McPherson, G. Goldberger, S. K. Karathanasis, and J. L. Breslow, “Synthesis, intracellular processing, and signal peptide of human apolipoprotein E,” Journal of Biological Chemistry, vol. 259, no. 9, pp. 5495–5499, 1984.

[38] Y. Zhao and T. Mazzone, “Transport and processing of endogenously synthesized ApoE on the macrophage cell surface,” Journal of Biological Chemistry, vol. 275, no. 7, pp. 4759–4765, 2000.

[39] J. Ito, Y. Nagayasu, Y. Miura, S. Yokoyama, and M. Michikawa, “Astrocyte’s endogenous apoE generates HDL-like lipoproteins using previously synthesized cholesterol through interaction with ABCA1,” Brain Research, vol. 1570, pp. 1–12, 2014.

[40] D. A. Elliott, C. S. Weickert, and B. Garner, “Apolipoproteins in the brain: implications for neurological and psychiatric disorders,” Journal of Clinical Lipidology, vol. 51, no. 4, pp. 555–573, 2010.

[41] R. W. Mahley, “Apolipoprotein E: cholesterol transport protein with expanding role in cell biology,” Science, vol. 240, no. 4852, pp. 622–630, 1988.

[42] B. Möckel, H. Zinke, R. Flach, B. Weiß, H. Weiler-Güttler, and H. G. Gassen, “Expression of apolipoprotein A-I in porcine brain endothelium in vitro,” Journal of Neurochemistry, vol. 62, no. 2, pp. 788–798, 1994.

[43] H. Weiler-Güttler, M. Sommerfeldt, A. Papandrikopoulos et al., “Synthesis of apolipoprotein A-I in pig brain microvascular endothelial cells,” Journal of Neurochemistry, vol. 54, no. 2, pp. 444–450, 1990.

[44] U. Panzenboeck, Z. Balazs, A. Sovic et al., “ABCA1 and scavenger receptor class B type I are modulators of reverse sterol transport at an in vitro blood-brain barrier constituted of porcine brain capillary endothelial cells,” The Journal of Biological Chemistry, vol. 277, no. 45, pp. 42781–42789, 2002.

[45] T. L. Lewis, D. Cao, H. Lu et al., “Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease,” The Journal of Biological Chemistry, vol. 285, no. 47, pp. 36958–36968, 2010.

[46] C. Reitz, M. Tang, J. Luchsinger, and R. Mayeux, “Relation of plasma lipids to Alzheimer disease and vascular dementia,” Archives of Neurology, vol. 61, no. 5, pp. 705–714, 2004.

[47] R. Giudice, D. Monti, C. Sarcinelli, A. Arciello, R. Piccoli, and G. F. Hu, “Amyloidogenic variant of apolipoprotein A-I elicits cellular stress by attenuating the protective activity of angiogenin,” Cell Death and Disease, vol. 5, Article ID e1097, 2014.

[48] V. Hirsch-Reinshagen, S. Zhou, B. L. Burgess et al., “Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain,” Journal of Biological Chemistry, vol. 279, no. 39, pp. 41197–41207, 2004.

[49] R. Koldamova, M. Staufenbiel, and I. Leferov, “Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice,” The Journal of Biological Chemistry, vol. 280, no. 52, pp. 43224–43235, 2005.

[50] L. Krimbou, M. Denis, B. Haidar, M. Marcil, and J. Genest Jr., “Molecular interactions between apoE and ABCA1: impact on apoE lipiddation,” Journal of Lipid Research, vol. 45, no. 5, pp. 839–848, 2004.

[51] S. E. Wahlre, H. Jiang, M. Parsadanian et al., “ABCA1 is required for normal central nervous system apoE levels and for lipidation of astrocyte-secreted apoE,” Journal of Biological Chemistry, vol. 279, no. 39, pp. 40987–40993, 2004.

[52] J. Ito, Y. Nagayasu, A. Kheirollah, S. Abe-Dohmae, and S. Yokoyama, “ApoA-I enhances generation of HDL-like lipoproteins through interaction between ABCA1 and phospholipase Cy in rat astrocytes,” Biochimica et Biophysica Acta, vol. 1811, no. 12, pp. 1062–1069, 2011.

[53] K. M. Smith, R. M. Lawn, and J. N. Wilcox, “Cellular localization of apolipoprotein D and lecithin: cholesterol acyltransferase mRNA in rhesus monkey tissues by in situ hybridization,” Journal of Lipid Research, vol. 31, no. 6, pp. 995–1004, 1990.
[54] M. Bodzioch, E. Orsó, J. Klucken et al., “The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease,” *Nature Genetics*, vol. 22, no. 4, pp. 347–351, 1999.

[55] A. Brooks-Wilson, M. Marcil, S. M. Clee et al., “Mutations in ABCI in Tangier disease and familial high-density lipoprotein deficiency,” *Nature Genetics*, vol. 22, no. 4, pp. 336–345, 1999.

[56] S. Rust, M. Rosier, H. Funke et al., “Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1,” *Nature Genetics*, vol. 22, no. 4, pp. 352–355, 1999.

[57] J. F. Oram, R. M. Lawn, M. R. Garvin, and D. P. Wade, “ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages,” *The Journal of Biological Chemistry*, vol. 275, no. 44, pp. 34508–34511, 2000.

[58] A. M. Vaughan and J. F. Oram, “ABCA1 redistributes membrane cholesterol independent of apolipoprotein interactions,” *Journal of Lipid Research*, vol. 44, no. 7, pp. 1373–1380, 2003.

[59] N. Wang, D. L. Silver, P. Costet, and A. R. Tall, “Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABCI,” *The Journal of Biological Chemistry*, vol. 275, no. 42, pp. 33053–33058, 2000.

[60] L. Yvan-Charvet, N. Wang, and A. R. Tall, “Role of HDL, ABCAI, and ABCG1 transporters in cholesterol efflux and immune responses,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 30, no. 2, pp. 139–143, 2010.

[61] Y. D. Landry, M. Denis, S. Nandi, S. Bell, A. M. Vaughan, and X. Zha, “ATP-binding cassette transporter A1 expression disrupts raft membrane microdomains through its ATPase-related functions,” *Journal of Biological Chemistry*, vol. 281, no. 47, pp. 36091–36101, 2006.

[62] W. Chen, Y. Sun, C. Welch et al., “Preferential ATP-binding cassette transporter A1-mediated cholesterol efflux from late endosomes/lysosomes,” *The Journal of Biological Chemistry*, vol. 276, no. 47, pp. 43564–43569, 2001.

[63] Y. Takahashi and J. D. Smith, “Cholesterol efflux to apolipoprotein A1 involves endocytosis and resecretion in a calcium-dependent pathway,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 96, no. 20, pp. 11358–11363, 1999.

[64] J. M. Sturek, J. D. Castle, A. P. Trace et al., “An intracellular role for ABCG1-mediated cholesterol transport in the regulated secretory pathway of mouse pancreatic β cells,” *Journal of Clinical Investigation*, vol. 120, no. 7, pp. 2575–2589, 2010.

[65] P. T. Tarr and P. A. Edwards, “ABCG1 and ABCG4 are coexpressed in neurons and astrocytes of the CNS and regulate cholesterol homeostasis through SREBP-2,” *Journal of Lipid Research*, vol. 49, no. 1, pp. 169–182, 2008.

[66] N. Wang, D. Lan, W. Chen, F. Matsuura, and A. R. Tall, “ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 26, pp. 9774–9779, 2004.

[67] B. Karten, R. B. Campenot, D. E. Vance, and J. E. Vance, “Expression of ABCG1, but not ABCA1, correlates with cholesterol release by cerebellar astroglia,” *The Journal of Biological Chemistry*, vol. 281, no. 7, pp. 4049–4057, 2006.

[68] A. Kheirollah, J. Ito, Y. Nagayasu, R. Lu, and S. Yokoyama, “Cyclosporin A inhibits apolipoprotein A-I-induced early events in cellular cholesterol homeostasis in rat astrocytes,” *Neuropharmacology*, vol. 51, no. 4, pp. 693–700, 2006.

[69] S. A. Pandit, S. Vasudevan, S. W. Chiu, R. J. Mashl, E. Jakobsson, and H. L. Scott, “Sphingomyelin-cholesterol domains in phospholipid membranes: atomistic simulation,” *Biophysical Journal*, vol. 87, no. 2, pp. 1092–1100, 2004.

[70] T. Róg and M. Pasenkiewicz-Gierula, “Cholesterol-sphingomyelin interactions: a molecular dynamics simulation study,” *Biophysical Journal*, vol. 91, no. 10, pp. 3756–3767, 2006.

[71] K. Simons and E. Ikonen, “Functional rafts in cell membranes,” *Nature*, vol. 387, no. 6633, pp. 569–572, 1997.

[72] J. Ito, Y. Nagayasu, and S. Yokoyama, “Cholesterol-sphingomyelin interaction in membrane and apolipoprotein-mediated cellular cholesterol efflux,” *Journal of Lipid Research*, vol. 41, no. 6, pp. 894–904, 2000.

[73] K. Nagao, K. Takahashi, K. Hanada, N. Kioka, M. Matsuo, and K. Ueda, “Enhanced ApoA-I-dependent cholesterol efflux by ABCA1 from sphingomyelin-deficient Chinese hamster ovary cells,” *The Journal of Biological Chemistry*, vol. 282, no. 20, pp. 14868–14874, 2007.

[74] J. Ito, A. Kheirollah, Y. Nagayasu, R. Lu, K. Kato, and S. Yokoyama, “Apolipoprotein A-I increases association of cytosolic cholesterol and caveolin-1 with microtubule cytoskeletons in rat astrocytes,” *Journal of Neurochemistry*, vol. 97, no. 4, pp. 1034–1043, 2006.

[75] J. Ito, R. Lu, Y. Nagayasu et al., “Apolipoprotein A-I induces tubulin phosphorylation in association with cholesterol release in fetal rat astrocytes,” *Biochimica Biophysica et Acta*, 2014.